Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody from ProteoGenix; catalogue ARO-A22519; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody
The Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody is a highly specific and sensitive tool for detecting the Omicron variant of the SARS-CoV-2 virus. This antibody targets the receptor-binding domain (RBD) of the virus, which is responsible for binding to the host cell receptor and initiating infection.
This antibody is primarily used for research purposes, specifically in the study of the Omicron variant of SARS-CoV-2. It can be used in various immunoassays, including ELISA, Western blot, and immunofluorescence, to detect the presence of the Omicron RBD protein.
The Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody has been successfully used in experimental studies to understand the characteristics and behavior of the Omicron variant. It has been used to study the binding affinity of the Omicron RBD to the host cell receptor, as well as its ability to evade neutralizing antibodies. This antibody has also been used in vaccine development studies to assess the effectiveness of different vaccine candidates against the Omicron variant.
With its high specificity and sensitivity, this antibody is an essential tool for researchers studying the Omicron variant and its impact on the COVID-19 pandemic.
This Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody is specifically designed for research purposes and is highly specific and sensitive in detecting the Omicron variant of the SARS-CoV-2 virus. Its main applications include ELISA, Western blot, and immunofluorescence, making it a versatile tool for studying the Omicron RBD protein. This antibody has been successfully used in experimental studies to understand the characteristics and behavior of the Omicron variant and its potential impact on vaccine development.
Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody
The Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody is a highly specific and sensitive tool for detecting the Omicron variant of the SARS-CoV-2 virus. This antibody targets the receptor-binding domain (RBD) of the virus, which is responsible for binding to the host cell receptor and initiating infection.
This antibody is primarily used for research purposes, specifically in the study of the Omicron variant of SARS-CoV-2. It can be used in various immunoassays, including ELISA, Western blot, and immunofluorescence, to detect the presence of the Omicron RBD protein.
The Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody has been successfully used in experimental studies to understand the characteristics and behavior of the Omicron variant. It has been used to study the binding affinity of the Omicron RBD to the host cell receptor, as well as its ability to evade neutralizing antibodies. This antibody has also been used in vaccine development studies to assess the effectiveness of different vaccine candidates against the Omicron variant.
With its high specificity and sensitivity, the Anti-RBD (Omicron/B.1.1.529) Polyclonal Antibody is an essential tool for researchers studying the Omicron variant and its impact on the COVID-19 pandemic. Its versatile applications and successful use in experimental studies make it a valuable asset in understanding and combatting this emerging variant.
ProteoGenix catalogue number ARO-A22519. For research use only.
Target: surface glycoprotein [Severe acute respiratory syndrome coronavirus 2], S, N-terminal domain of the S1 subunit of the Spike (S) protein from Severe acute respiratory syndrome coronavirus and related betacoronaviruses in the B lineage; cd21624, trimer interface [polypeptide binding], receptor-binding domain of the S1 subunit of coronavirus spike (S) proteins; cl40478, trimer interface [polypeptide binding], putative receptor binding site [polypeptide binding], receptor binding motif, SD-1 and SD-2 subdomains, the S1/S2 cleavage region, and the S2 fusion subunit of the spike (S) glycoprotein from SARS-CoV-2 (COVID-19) and related betacoronaviruses in the B lineage; cd22378, N-linked glycosylation sites [posttranslational modification], S1/S2 cleavage region, S1/S2 furin cleavage site, fusion peptide, internal fusion peptide, heptad repeat 1 [structural motif], heptad repeat 2 [structural motif]; Clonality: Polyclonal Antibody; Applications: IHC, ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| surface glycoprotein Severe acute respiratory syndrome coronavirus 2, S, N-terminal domain of the S1 subunit of the Spike (S) protein from Severe acute respiratory syndrome coronavirus and related betacoronaviruses in the B lineage; cd21624, trimer interface polypeptide binding, receptor-binding domain of the S1 subunit of coronavirus spike (S) proteins; cl40478, trimer interface polypeptide binding, putative receptor binding site polypeptide binding, receptor binding motif, SD-1 and SD-2 subdomains, the S1/S2 cleavage region, and the S2 fusion subunit of the spike (S) glycoprotein from SARS-CoV-2 (COVID-19) and related betacoronaviruses in the B lineage; cd22378, N-linked glycosylation sites posttranslational modification, S1/S2 cleavage region, S1/S2 furin cleavage site, fusion peptide, internal fusion peptide, heptad repeat 1 structural motif, heptad repeat 2 structural motif |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
